[go: up one dir, main page]

WO2006060774A3 - Agents that inhibit flavivirus replication and uses thereof - Google Patents

Agents that inhibit flavivirus replication and uses thereof Download PDF

Info

Publication number
WO2006060774A3
WO2006060774A3 PCT/US2005/043938 US2005043938W WO2006060774A3 WO 2006060774 A3 WO2006060774 A3 WO 2006060774A3 US 2005043938 W US2005043938 W US 2005043938W WO 2006060774 A3 WO2006060774 A3 WO 2006060774A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
flavivirus replication
inhibit flavivirus
inhibit
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/043938
Other languages
French (fr)
Other versions
WO2006060774A2 (en
Inventor
Scott R Gilbertson
Pedro J Lory
Robert D Malmstrom
Yuan-Ping Pang
Andrew T Russo
Stanley J Watowich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
University of Texas System
University of Texas at Austin
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
University of Texas System
University of Texas at Austin
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, University of Texas System, University of Texas at Austin, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of WO2006060774A2 publication Critical patent/WO2006060774A2/en
Publication of WO2006060774A3 publication Critical patent/WO2006060774A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/16—Oxygen atoms, e.g. thioxanthones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides compounds with activity against a variety of flaviviruses, uses thereof, and methods for identifying such compounds.
PCT/US2005/043938 2004-12-02 2005-12-02 Agents that inhibit flavivirus replication and uses thereof Ceased WO2006060774A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63274904P 2004-12-02 2004-12-02
US60/632,749 2004-12-02

Publications (2)

Publication Number Publication Date
WO2006060774A2 WO2006060774A2 (en) 2006-06-08
WO2006060774A3 true WO2006060774A3 (en) 2007-03-22

Family

ID=36565839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/043938 Ceased WO2006060774A2 (en) 2004-12-02 2005-12-02 Agents that inhibit flavivirus replication and uses thereof

Country Status (1)

Country Link
WO (1) WO2006060774A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7480400B2 (en) 2006-03-16 2009-01-20 Siemens Medical Solutions Usa, Inc. Detection of fiber pathways
GB2443892B (en) * 2007-01-13 2010-11-24 Shahnaz Perveen "Gaschem " a urease and alpha-chymotrypsin enzyme inhibito ry drug
PT2308514E (en) 2007-03-23 2013-09-06 To Bbb Holding B V Conjugates for targeted drug delivery across the blood-brain barrier
JP6091636B2 (en) * 2012-11-08 2017-03-08 中国科学院理化技術研究所 Thioxanthone oxide derivative, production method and application thereof
CN113429238A (en) * 2021-07-23 2021-09-24 甘肃省农业科学院旱地农业研究所 Organic fertilizer and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] COATES ET AL.: "New Therapeutic agents of the quinoline series. Introduction and II. Methoxy-, hydroxy-, and alkylpyridylquinolines", XP003009984, Database accession no. (1944:520) *
DATABASE CAPLUS [online] COOK A.H. ET AL.: "New Therapeutic agents of the quinoline series, Introduction and IV. Lutidylquinolines", XP003009983, Database accession no. (1944:521) *
J. CHEM. SOCIETY, 1943, pages 406 - 413 *
J. CHEM. SOCIETY, 1943, pages 413 - 417 *

Also Published As

Publication number Publication date
WO2006060774A2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006120176A3 (en) Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
WO2006056399A3 (en) Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2006104911A3 (en) Methods and compositions for modulating hyperstabilized c-met
WO2008127226A3 (en) P13 kinase antagonists
WO2006091529A3 (en) A solid pharmaceutical dosage formulation
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
IL182061A0 (en) Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
WO2006071762A3 (en) Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2004101742A3 (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
IL180879A0 (en) Methods and compositions for inhibiting, destroying, and/or inactivating viruses
CA115145S (en) Ink cartridge
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
CA115126S (en) Ink cartridge
CA115127S (en) Ink cartridge
WO2007076159A3 (en) Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
CA115124S (en) Ink cartridge
WO2006034035A3 (en) Treatment of ischemia
WO2006060774A3 (en) Agents that inhibit flavivirus replication and uses thereof
WO2007116029A3 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
WO2006098998A3 (en) Methods and compositions for modulating vascular integrity
WO2007042465A3 (en) Combinati0n of nilotinib with farnesyl transferase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05852989

Country of ref document: EP

Kind code of ref document: A2